3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
3
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Gynecologic
1
Breast
1
Conditions
Solid Tumors Harboring a BRAF V600 Mutation
1
Solid Tumors
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
1
Breast Neoplasms
1
Interventions
Filgrastim
2
Carboplatin
2
ribociclib
1
enzalutamide
1
belinostat
1
becatecarin
1
abemaciclib
1
Topotecan
1
Thiotepa
1
Sirolimus
1
Peripheral Blood Stem Cell Transplantation
1
Pemetrexed
1
Midazolam
1
Letrozole
1
LY3023414
1
Immunotherapy, Adoptive
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Granulocyte Colony-Stimulating Factor
1
Fulvestrant
1
Etoposide
1
Doxepin
1
Cisplatin
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
ribociclib
×
Other solid neoplasm
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts